Preferred Label : Leriglitazone;
NCIt synonyms : 2,4-Thiazolidinedione, 5-((4-(2-(5-(1-Hydroxyethyl)-2-pyridinyl)ethoxy)phenyl)methyl)-;
NCIt definition : An orally bioavailable, blood-brain-barrier (BBB) penetrable, selective peroxisome
proliferator-activated receptor (PPAR) subtype gamma agonist, with potential neuroprotective
activity that could be used for certain central nervous system (CNS) diseases, such
as adrenomyeloneuropathy, cerebral adrenoleukodystrophy (cALD), Friedreich's ataxia,
and certain other CNS diseases. Upon oral administration, leriglitazone selectively
targets, binds to and activates PPARgamma, thereby regulating the expression of genes
involved in mitochondrial biogenesis. This modulates pathways leading to the restoration
of mitochondrial function in which dysfunction is caused by the accumulation of very
long-chain fatty acids (VLCFAs), and increases energy production, decreases oxidative
stress, decreases nuclear factor kappa B (NF-kB) levels, inhibits neuroinflammation,
protects the BBB integrity, prevents demyelination and axonal degeneration, increases
neuronal survival, increases myelination and oligodendrocyte survival and improves
motor function. Mutations in the ABCD1 gene, which encodes the peroxisomal membrane
adrenoleukodystrophy protein, cause a defective function of the ABCD1 transporter
leading to an accumulation of VLCFA. VLCFA accumulation contributes to membrane destabilization
of the myelin sheath, mitochondrial dysfunction, oxidative stress, neuroinflammation
and compromised BBB integrity.;
UNII : K824X25AYA;
InChIKey : OXVFDZYQLGRLCD-UHFFFAOYSA-N;
CAS number : 146062-44-4;
Molecule name : MIN 102; MIN-102;
NCI Metathesaurus CUI : CL1382351;
Origin ID : C170108;
UMLS CUI : C5139806;
Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_salt_form
- is_free_acid_or_base_form_of
